Cooperation between Zedira and Cardiff University
Transglutaminase 6 is the focus of new research into ataxia
Cerebellar ataxias are a heterogeneous group of neurodegenerative diseases affecting primarily the hind brain and are characterized by progressive imbalance and limb movement deficits. Both, genetic and immune-mediated deficiencies in transglutaminase 6 have been implicated in specific forms of adult onset cerebellar ataxia. Within this new project the partners aim to elucidate the underlying processes that ultimately cause disease. A molecular understanding of the disease process and identification of mechanistic links to other ataxias will inform the design of strategies for therapeutic intervention.
Ralf Pasternack / Martin Hils, CEO Zedira: “We are excited about working with Prof. Aeschlimann’s research group with world-leading expertise in this area”.
Daniel Aeschlimann, Cardiff University comments: “The combination of Zedira’s molecular tools, drug candidates and know-how in the transglutaminase field with our scientific expertise is a solid fundament for addressing this thus far unexplored research area”.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.